Objectives: To systematically review the literature pertaining to the prevalence of depression and anxiety in patients with ovarian cancer as a function of treatment stage.
Design: Systematic review and meta-analysis.
Participants: 3623 patients with ovarian cancer from primary research investigations.
Primary Outcome Measure: The prevalence of depression and anxiety in patients with ovarian cancer as a function of treatment stage.
Results: We identified 24 full journal articles that met the inclusion criteria for entry into the meta-analysis resulting in a pooled sample size of 3623 patients. The meta-analysis of prevalence rates identified pretreatment, on-treatment and post-treatment depression prevalences of 25.34% (CI 22.79% to 28.07%), 22.99% (CI 19.85% to 26.46%) and 12.71% (CI 10.14% to 15.79%), respectively. Pretreatment, on-treatment and post-treatment anxiety prevalences were 19.12% (CI 17.11% to 21.30%), 26.23% (CI 22.30% to 30.56%) and 27.09% (CI 23.10% to 31.49%).
Conclusions: Our findings suggest that the prevalence of depression and anxiety in women with ovarian cancer, across the treatment spectrum, is significantly greater than in the healthy female population. With the growing emphasis on improving the management of survivorship and quality of life, we conclude that further research is warranted to ensure psychological distress in ovarian cancer is not underdiagnosed and undertreated.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679843 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2015-007618 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
REV7: a small but mighty regulator of genome maintenance and cancer development.
Front Oncol
January 2025
Department of Biology, Tufts University, Medford, MA, United States.
REV7, also known as MAD2B, MAD2L2, and FANCV, is a HORMA-domain family protein crucial to multiple genome stability pathways. REV7's canonical role is as a member of polymerase ζ, a specialized translesion synthesis polymerase essential for DNA damage tolerance. REV7 also ensures accurate cell cycle progression and prevents premature mitotic progression by sequestering an anaphase-promoting complex/cyclosome activator.
View Article and Find Full Text PDFIncorporating genotype information in a precise prediction model for platinum sensitivity in epithelial ovarian cancer.
Front Oncol
January 2025
Department of Gynecology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Objective: Develop a predicting model that can help stratify patients with epithelial ovarian cancer (EOC) before platinum-based chemotherapy.
Methods: 148 patients with pathologically confirmed EOC and with a minimum 5-year follow-up were retrospectively enrolled. Patients were classified into platinum-sensitive and platinum-resistant groups according to treatment responses.
Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer.
Front Oncol
January 2025
Department of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, Minneapolis, MN, United States.
Genomic analysis has played a significant role in the identification of driver mutations that are linked to disease progression and response to drug treatment in ovarian cancer. A prominent example is the stratification of epithelial ovarian cancer (EOC) patients with homologous recombination deficiency (HRD) characterized by mutations in DNA damage repair genes such as for treatment with PARP inhibitors. However, recent studies have shown that some epithelial ovarian tumors respond to PARP inhibitors irrespective of their HRD or mutation status.
View Article and Find Full Text PDFEndometrial cancer with para-aortic lymph node metastasis following medroxyprogesterone acetate therapy: A case report.
J Obstet Gynaecol Res
January 2025
Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical University, Tochigi, Japan.
Medroxyprogesterone acetate (MPA) is a promising fertility-sparing treatment for early stage endometrial cancer; however, it has a high recurrence rate and is inferior to surgery. Although the site of recurrence is mostly the endometrium, we here report a case of metastatic recurrence to the para-aortic lymph node with endometrial recurrence despite a careful follow-up. A 31-year-old woman was diagnosed with grade 1 endometrioid carcinoma, stage IA without myometrial invasion.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!